Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET. Company Participants. Robin C. Kramer - Executive VP & CFO. Conference ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

that Biogen is building on a new foundation with the goal of long-term sustainable growth in its commercial portfolio; the multi-billion dollar potential of its late-stage pipeline; that we believe ...

that Biogen is building on a new foundation with the goal of long-term sustainable growth in its commercial portfolio; the multi-billion dollar potential of its late-stage pipeline; that we ...

Jefferies warned that this royalty could see a 50% reduction by 2030 due to biosimilar competition, posing a 20-30% hit to Biogen’s earnings power. “This is why they need more pipeline and ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi ...